Citius Pharma Q3 fiscal 2025 net loss narrows to $9.2M; LYMPHIR launch on track for Q4

Citius Pharmaceuticals, Inc.

2025-Q3 EPS reported -$3.27

Net loss of $9.2M ($0.80 per share) vs $10.6M ($1.57 per share) in the prior-year quarter.
Cash and equivalents $6.1M at June 30; raised $12.5M in gross financings during the quarter.
LYMPHIR launch for cutaneous T-cell lymphoma planned Q4 2025; manufacturing and distribution agreements in place.
Citius Oncology raised additional $9M in July 2025 to fund pre-launch activities.
Mino-Lok discussions with FDA continue; evaluating best path forward for antibiotic lock solution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.